Ponatinib as first treatment for Ph+ acute lymphoblastic leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies how well the drug ponatinib works in people with Ph+ ALL when it is used as the first treatment. It looks at real-world outcomes to understand the drug's effectiveness in everyday practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have a type of leukemia called Ph+ ALL (Philadelphia chromosome-positive acute lymphoblastic leukemia)
- You received ponatinib as your first treatment (alone, with chemotherapy, or with immunotherapy)
- Your treatment followed a specific Italian law (Law 648/96) for drug access
- You either have at least 18 months of follow-up since starting ponatinib, or you have passed away or been lost to follow-up at any point
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of chemotherapy, targeted pills (imatinib or ponatinib), and a targeted immunotherapy (blinatumomab) before a stem cell transplant for adults with a specific type of leukemia called Philadelphia chromosome-positive ALL. The goal is to find the best treatment approach.
This trial tests a targeted therapy called ponatinib in children whose leukemia, lymphoma, or solid tumor has come back or hasn't improved with standard treatments. The drug works by blocking signals that help cancer cells grow, and the study looks at how safe and effective it is for different cancer types.
This trial tests a combination of chemotherapy drugs (EPOCH) plus a targeted therapy (ponatinib) for patients with a specific type of acute lymphoblastic leukemia (Ph+ ALL). Some participants also get rituximab if their leukemia cells have a certain marker (CD20). The goal is to see how well this treatment works as a first therapy.
This trial tests a combination of two drugs for adults newly diagnosed with a specific type of acute lymphoblastic leukemia that has the Philadelphia chromosome. The goal is to see if this combination is safe and effective.
This trial studies ponatinib as a second treatment for chronic myeloid leukemia (CML) when it didn’t fully respond or couldn’t be tolerated with at least one prior CML pill. It aims to see whether ponatinib can better control leukemia levels after earlier treatments.
This study looks at how the drug ponatinib works in people with chronic phase CML. It aims to understand how the body handles the drug and if it helps control the leukemia.
Hear when a new Acute Lymphobkastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.